|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lately, FDG PET/CT-derived parameters, such as standardized uptake values (SUV), the metabolic tumor volume (MTV), and total lesion glycolysis (TLG), have been suggested as prognostic factors for various types of cancer, including pancreatic cancer.
|
30629646 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The value of <sup>18</sup>F-FDG PET/CT and carbohydrate antigen 19-9 in predicting lymph node micrometastases of pancreatic cancer.
|
31570958 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG-PET has an important and promising role for pancreatic cancer.
|
30940428 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed at clarifying both the prognostic role and assessment value of FDG-PET in pancreatic carcinoma.
|
31404025 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the prognostic roles of F-FDG PET/CT metabolic parameters and clinical figures in LAPC patients underwent chemo-SBRT combined therapy.During January 2013 to January 2017, 23 LAPC patients who underwent F-FDG PET/CT within 2 weeks before treatment were recruited and retrospectively analyzed.
|
30921238 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fifty-two LAPC patients (median age: 61 years; range: 35-85) with available FDG PET/CT before and after RT (2-6 months, median: 2) were enrolled from May 2005 to June 2015.
|
31365502 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An F-FDG PET/CT was performed on a 74-year-old woman with pancreatic carcinoma and liver metastases.
|
30300198 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
|
29782393 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We present a case of focal autoimmune pancreatitis with abnormal FDG activity involving only the pancreatic tail on PET/CT in a 61-year-old man who was provisionally diagnosed as having pancreatic cancer based on the CT findings.
|
29189377 |
2018 |
|
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Focal abnormal pancreatic FDG activities were found in 38/40 (95.00%) PC patients, while longitudinal were found in 18/26 (69.23%) AIP patients.
|
29061130 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/CT showed increased FDG accumulation not only in the pancreas and the retroperitoneum, but also in the posterior mediastinum, which was not typical of pancreatic carcinoma.
|
28806261 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.
|
28774338 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study evaluated the relationship between Glut-1 expression and FDG accumulation to determine the usefulness of FDG-PET for prediction of long-term outcomes of pancreatic cancer.
|
28180987 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This meta-analysis was performed to comprehensively explore the prognostic significance of F-FDG-PET/CT parameters in patients with pancreatic carcinoma.
|
28816978 |
2017 |